Form 4: Niagen Bioscience Director and 10% Owner Acquires Significant Stock Options

Ng Wang Yu Gary, a Director and 10% owner of Niagen Bioscience, Inc., has acquired 20,000 stock options with an exercise price of $14.13, vesting fully on June 24, 2026.

Summary

• Ng Wang Yu Gary, identified as both a Director and a 10% owner of Niagen Bioscience, Inc. (NAGE), acquired 20,000 stock options.
• The acquired stock options have an exercise price of $14.13 per share.
• These options are scheduled to vest 100% on June 24, 2026.
• The expiration date for these stock options is June 23, 2035.
• Following this transaction, Ng Wang Yu Gary directly beneficially owns 20,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director and 10% owner is generally a positive signal, indicating insider confidence in the company's future prospects. However, this filing does not provide operational or financial performance updates, limiting the overall sentiment score to reflect only the insider's action.

Positives

• The acquisition of stock options by a Director and 10% owner indicates a strong alignment of interests with shareholders, suggesting confidence in the company's future performance and potential stock price appreciation.
• The long expiration date (June 23, 2035) provides a significant window for the options to become in-the-money, reflecting a long-term perspective.

Negatives

• This Form 4 filing primarily reports an insider transaction and does not contain information that would typically be categorized as negative regarding the company's operational or financial performance.

Risks

• The value of the acquired stock options is contingent upon the future market price of Niagen Bioscience, Inc. common stock exceeding the exercise price of $14.13.
• If the company's stock price does not rise above the exercise price by the expiration date, the options may expire worthless, resulting in no financial gain for the holder.

Future Outlook

This Form 4 filing reports a specific insider transaction and does not provide forward-looking statements or guidance from Niagen Bioscience, Inc. regarding its business operations or financial performance. It only details the future vesting and expiration dates of the acquired stock options.

Industry Context

The acquisition of stock options by a director and significant owner is a common practice in corporate compensation structures, aiming to align the interests of management with those of shareholders. This specific transaction reflects an individual's equity position rather than broader industry trends.

Related Party Transactions

• Acquisition of 20,000 stock options by Ng Wang Yu Gary, a Director and 10% owner of Niagen Bioscience, Inc., from the company. This constitutes a related party transaction as it involves an insider and the issuer.

Stakeholder Impact

• Shareholders: The transaction may be perceived as a positive signal of management's confidence in the company's future, potentially influencing investor sentiment and stock valuation.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The acquired stock options will vest 100% on June 24, 2026.
• The reporting person can exercise these options at any time after vesting until their expiration on June 23, 2035.

Key Dates

Keywords

Niagen Bioscience, NAGE, Form 4, stock options, insider transaction, director, beneficial ownership, equity compensation, SEC filing